MARKETS
Analyst Actions

BTIG Reiterates Buy on Serina Therapeutics, Maintains $8 Price Target

Oct 26, 2026 · 05:51 AM ET· updated 9h ago

BTIG analyst Thomas Shrader reiterates Serina Therapeutics (AMEX:SER) with a Buy and maintains $8 price target.

Share
Why It Matters

A stock expert says Serina Therapeutics is still a good company to watch. They think the stock could be worth around $8 per share.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.